TSS
ADXN

Two Sigma Securities’s Addex Therapeutics ADXN Stock Holding History

Two Sigma Securities’s Portfolio ADXN Stock Details ADXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-604
Closed -$10K – 2526
2022
Q3 		$10K Buy
+604
New +$13.5K ﹤0.01% 2396

Other funds holding ADXN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Two Sigma Securities's ADXN Position: Q4 2022 in Review

Two Sigma Securities sold out of Addex Therapeutics (ADXN) in Q4 2022, closing a stake of 604 shares — an estimated $10K sold.

Two Sigma Securities first reported a position in ADXN in Q3 2022 and held it in 1 quarter. The position peaked at $10K in Q3 2022. 8 funds tracked by Wall St. Rank hold ADXN as of Q4 2022.

  • Two Sigma Securities reported no remaining Addex Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Two Sigma Securities sold 604 Addex Therapeutics shares in Q4 2022, an estimated $10K.
  • Two Sigma Securities first reported a position in Addex Therapeutics in Q3 2022 and held it in 1 quarter.
  • Two Sigma Securities's Addex Therapeutics position peaked at $10K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Addex Therapeutics as of Q4 2022.

Based on Two Sigma Securities's 13F filing for Q4 2022, filed 14 Feb 2023.